296 related articles for article (PubMed ID: 34480522)
1. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
Karam JA; Puligandla M; Flaherty KT; Uzzo RG; Matin SF; Pins MR; Wood CG; Kane C; Jewett MAS; Kim SE; Dutcher JP; DiPaola RS; Haas NB
BJU Int; 2022 Jun; 129(6):718-722. PubMed ID: 34480522
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
[TBL] [Abstract][Full Text] [Related]
4. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
[TBL] [Abstract][Full Text] [Related]
5. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
Jilaveanu LB; Puligandla M; Weiss SA; Wang XV; Zito C; Flaherty KT; Boeke M; Neumeister V; Camp RL; Adeniran A; Pins M; Manola J; DiPaola RS; Haas NB; Kluger HM
Clin Cancer Res; 2018 Jan; 24(1):217-223. PubMed ID: 29066509
[No Abstract] [Full Text] [Related]
6. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
7. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
Xu W; Puligandla M; Halbert B; Haas NB; Flaherty KT; Uzzo RG; Dutcher JP; DiPaola RS; Sabbisetti V; Bhatt RS
Clin Cancer Res; 2021 Jun; 27(12):3397-3403. PubMed ID: 33832947
[TBL] [Abstract][Full Text] [Related]
8. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
Zhao F; Cella D; Manola J; DiPaola RS; Wagner LI; Haas NSB
Support Care Cancer; 2018 Jun; 26(6):1889-1895. PubMed ID: 29274030
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
Narayan V; Puligandla M; Haas NB; Subramanian P; DiPaola RS; Uzzo R
J Urol; 2019 Jan; 201(1):62-68. PubMed ID: 30130544
[TBL] [Abstract][Full Text] [Related]
11. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
Ristau BT; Manola J; Haas NB; Heng DYC; Messing EM; Wood CG; Kane CJ; DiPaola RS; Uzzo RG
J Urol; 2018 Jan; 199(1):53-59. PubMed ID: 28728992
[TBL] [Abstract][Full Text] [Related]
12. Association between age and sex and mortality after adjuvant therapy for renal cancer.
Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
[TBL] [Abstract][Full Text] [Related]
13. Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort.
Jamil ML; Keeley J; Sood A; Dalela D; Arora S; Peabody JO; Trinh QD; Menon M; Rogers CG; Abdollah F
Eur Urol; 2020 Feb; 77(2):277-281. PubMed ID: 31703971
[TBL] [Abstract][Full Text] [Related]
14. Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trial.
Murphy CC; Fullington HM; Gerber DE; Bowman IA; Puligandla M; Dutcher JP; DiPaola RS; Haas NB
Cancer Med; 2021 Sep; 10(17):5917-5924. PubMed ID: 34405965
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA; Hariharan S; Chudnovsky A; Ching KA; Mu XJ; Mariani M; Robbins PB; Huang B; di Pietro A; Albiges L
ESMO Open; 2021 Jun; 6(3):100101. PubMed ID: 33901870
[TBL] [Abstract][Full Text] [Related]
18. Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
Carthon BC; Kim SE; McDermott DF; Dutcher JP; Puligandla M; Manola J; Pins M; Carducci MA; Plimack ER; Appleman LJ; MacVicar GR; Kohli M; Kuzel TM; DiPaola RS; Haas NB
Clin Genitourin Cancer; 2023 Oct; 21(5):546-554. PubMed ID: 37455214
[TBL] [Abstract][Full Text] [Related]
19. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
